Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
9.9900
-0.6500 (-6.11%)
NASDAQ · Last Trade: May 8th, 1:27 AM EDT
Detailed Quote
Previous Close
10.64
Open
10.91
Bid
9.990
Ask
10.48
Day's Range
9.910 - 11.12
52 Week Range
9.660 - 25.07
Volume
4,290,649
Market Cap
694.15M
PE Ratio (TTM)
-2.595
EPS (TTM)
-3.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,458,939
Chart
About Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is dedicated to discovering and advancing novel drugs that aim to enhance patient outcomes by targeting specific mechanisms of cancer progression, particularly through immuno-oncology and epigenetic modulation. Syndax is actively engaged in multiple clinical trials to evaluate the efficacy and safety of its product candidates, which are designed to leverage the body's immune system and improve therapeutic responses in various malignancies. By fostering collaborations and pursuing a strategic pipeline, Syndax seeks to provide new options for patients battling cancer. Read More
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025.
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.
JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious post-transplant condition.
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs.).
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.
